Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 458.12 USD -1.55% Market Closed
Market Cap: 60.5B USD

Wall Street
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 492.12 USD with a low forecast of 238.36 USD and a high forecast of 609 USD.

Lowest
Price Target
238.36 USD
48% Downside
Average
Price Target
492.12 USD
7% Upside
Highest
Price Target
609 USD
33% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
BAVA
Bavarian Nordic A/S
34% Upside
ALT
Altimmune Inc
261% Upside
ZEAL
Zealand Pharma A/S
50% Upside
PGEN
Precigen Inc
141% Upside
IMNM
Immunome Inc
24% Upside
1801
Innovent Biologics Inc
17% Upside
ARX
Aroa Biosurgery Ltd
28% Upside
PRME
Prime Medicine Inc
83% Upside

Revenue
Forecast

Revenue Estimate
Alnylam Pharmaceuticals Inc

For the last 13 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 29%. The projected CAGR for the next 3 years is 46%.

29%
Past Growth
46%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALNY's stock price target?
Price Target
492.12 USD

According to Wall Street analysts, the average 1-year price target for ALNY is 492.12 USD with a low forecast of 238.36 USD and a high forecast of 609 USD.

What is Alnylam Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
46%

For the last 13 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 29%. The projected CAGR for the next 3 years is 46%.

Back to Top